Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Actinium PharmaceuticalsATNM -0.88%17 Net-Net Working Capital is $0.85 as of Jun. 2026. GuruFocus rates ATNM with a GF Score™ of 17/100. The stock has 4 warning signs investors should review. Among 818 Biotechnology companies, Actinium Pharmaceuticals ranks better than 89.49% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Actinium Pharmaceuticals's Net-Net Working Capital for the quarter that ended in Jun. 2026 was $0.85.
The industry rank for Actinium Pharmaceuticals's Net-Net Working Capital or its related term are showing as below:
ATNM's Price-to-Net-Net-Working-Capital is ranked better than 89.49% of 818
companies
in the Biotechnology industry
Industry Median: 5.3
vs ATNM: 1.32
Actinium Pharmaceuticals (AMEX:ATNM) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Actinium Pharmaceuticals Net-Net Working Capital Related Terms
Actinium Pharmaceuticals Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Actinium Pharmaceuticals's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Actinium Pharmaceuticals Net-Net Working Capital Chart
ATNM vs PSTV, IGC, PVCT: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Actinium Pharmaceuticals's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Actinium Pharmaceuticals Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Actinium Pharmaceuticals's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.85 mean?
Actinium Pharmaceuticals (ATNM) has a Net-Net Working Capital of $0.85 as of Jun. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Actinium Pharmaceuticals According to the industry distribution chart, Actinium Pharmaceuticals ranks #86 out of 818 companies in the Biotechnology industry, placing it in the top 10.5%.
Is Actinium Pharmaceuticals' Net-Net Working Capital too high?
Actinium Pharmaceuticals' current Net-Net Working Capital is $0.85. The Biotechnology industry median Net-Net Working Capital is 5.30. Actinium Pharmaceuticals' value of $0.85 is 84% below this industry median. Based on the distribution chart, Actinium Pharmaceuticals ranks #86 out of 818 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Actinium Pharmaceuticals has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Actinium Pharmaceuticals' Net-Net Working Capital compare to PSTV and IGC?
According to the Biotechnology industry distribution chart, Actinium Pharmaceuticals ranks #86 out of 818 companies for Net-Net Working Capital. This places Actinium Pharmaceuticals in the top 11% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 5.30. Actinium Pharmaceuticals' value of $0.85 is 84% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.30, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Actinium Pharmaceuticals's current Net-Net Working Capital of $0.85 is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Actinium Pharmaceuticals For the Biotechnology industry, the median Net-Net Working Capital is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Actinium Pharmaceuticals's current Net-Net Working Capital is $0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinium Pharmaceuticals stock overvalued right now?
Actinium Pharmaceuticals (ATNM) has a current Net-Net Working Capital of $0.85. The current Net-Net Working Capital is $0.85 and 84% below the Biotechnology industry median of 5.30. Actinium Pharmaceuticals' overall GF Score™ is 17/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Actinium Pharmaceuticals (ATNM), the current Net-Net Working Capital is $0.85 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
17GF Score
Get the complete analysis for ATNM
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATNM has been successfully added to your 
